In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selected Start-Ups (09/00)

Executive Summary

In Vivo summarizes the technologies of several recently founded companies: Ardana Bioscience Ltd., spun-out in July from Britain's Medical Research Council, will commercialize research related to contraception and women's health. DiscoveRx will use proprietary enzyme fragment technology originally developed for clinical assays for SNP detection, to identify and validate drug targets, screen for drug leads, and collect pharmakinetic data on drugs in development. Fluorous Technologies Inc. was formed in June to commercialize fluorous organic chemistry technology developed by University of Pittsburgh chemistry professor Dennis P. Curran, PhD. Created by the founders of Geneva Bioinformatics Inc., Geneva Proteomics Inc. will obtain proteomic data by analyzing biologic fluids and tissues in health and sick individuals, enhance the data through bioinformatics, and sell information and synthesized proteins to clients. Hyalose LLC will commercialize unique recombinant technology developed by Paul H. Weigel, PhD and Paul L. DeAngelis, PhD at the University of Oklahoma Health Sciences Center (OUHSC) for the production of designer hyaluronan and novel polysaccharides. CMEA, Bay City, MPM and Versant are backing Syrrx Inc., a new entrant in the structural genomics field.
Advertisement
Advertisement
UsernamePublicRestriction

Register

IV001495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel